GlassScriptPhysician profile
Amy S Almany
NPI 1730699505
$9,586.29
in general payments reported to CMS, 2019-2025
43 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,855 · 2022: $2,474 · 2023: $2,065 · 2024: $1,840 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,232 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,232.44 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,148.60 | 2021-2025 | Tezspire, Farxiga, Fasenra |
| Novo Nordisk INC | $1,267.98 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $1,133.39 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $811.72 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $668.68 | 2021-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $550.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $367.04 | 2021-2025 | |
| Amgen INC. | $358.12 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $285.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $258.94 | 2021-2025 | |
| Mylan Specialty L.P. | $175.50 | 2022-2024 | Yupelri |
| Abbvie INC. | $159.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.68 | 2023-2024 | Glassia, Trintellix, Aralast |
| E.R. Squibb & Sons, L.L.C. | $108.91 | 2022-2025 | Eliquis, Camzyos |
| Currax Pharmaceuticals LLC | $84.73 | 2021-2023 | Contrave, Nexletol |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Almany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.